Understanding Arrhythmogenic Cardiomyopathy and its Treatment
Risk Stratification, Early Prevention and Treatment Strategies for Arrhythmogenic Cardiomyopathy (STARTER): a Multicenter Retro-prospective Cohort Study
This study is trying to learn more about Arrhythmogenic Cardiomyopathy by collecting health information and samples from patients to see how the condition behaves and what the long-term outcomes are.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | First Affiliated Hospital Xi'an Jiaotong University Academic / other |
| Locations | 1 site (Xi'an, Shaanxi) |
| Trial ID | NCT06352307 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients diagnosed with Arrhythmogenic Cardiomyopathy (ACM) at the First Affiliated Hospital of Xi'an Jiaotong University and other centers. It aims to collect clinical data and biological samples from patients with various ACM phenotypes. By establishing a disease cohort and conducting long-term follow-ups, the study will explore the characteristics, progression, clinical features, natural course, and long-term prognosis of ACM.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who have been diagnosed with Arrhythmogenic Cardiomyopathy.
Not a fit: Patients with incomplete clinical data or those who do not consent to participate will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved risk stratification and early treatment strategies for patients with Arrhythmogenic Cardiomyopathy.
How similar studies have performed: Other studies have explored similar approaches in understanding ACM, but this specific cohort and methodology may provide novel insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \>18 years old. * The diagnosis of ACM was confirmed by cardiac ultrasound, electrocardiogram, magnetic resonance angiography, pathological examination and gene sequencing. * Patients or their families agreed to participate in the study and authorized informed consent. Exclusion Criteria: * Incomplete clinical data. * Do not agree to the inclusion or refuse to authorize the informed consent.
Where this trial is running
Xi'an, Shaanxi
- First Affiliated Hospital of Xi'an Jiantong University — Xi'an, Shaanxi, China (Recruiting)
Study contacts
- Principal investigator: Yang Yan — First Affiliated Hospital Xi'an Jiaotong University
- Study coordinator: Yang Yan
- Email: yangyan3@xjtu.edu.cn
- Phone: +86.29.85323869
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.